Osteopontin Levels in Maternal Serum, Cord Blood, and Breast Milk According to Gestational Diabetes Mellitus: A Case-Control Study Authors: Merve Küçükoğlu Keser, Dilek Şahin, Sıddika Songül Yalçın Published: 2024 ABSTRACT Background/Objectives: The prevalence of gestational diabetes mellitus (GDM) is increasing, and GDM poses health risks for both mothers and newborns. This study investigated the association between GDM and two biomarkers, osteopontin (OPN) and betatrophin (ANGPTL8). Methods: This study involved face-to-face interviews with 165 participants—81 in the GDM group and 84 in the control group—to gather maternal-newborn data. Maternal serum OPN levels, along with cord serum OPN and ANGPTL8 levels, were measured at birth. OPN levels in breast milk were also measured between postnatal days 10–15. Statistical analysis included Student’s t-test for comparing biomarker levels, chi-square tests for GDM incidence across OPN quartile levels, multiple logistic regression for assessing GDM frequency by OPN quartile levels, and the Pearson correlation coefficient to explore relationships between biomarker levels and maternal-newborn characteristics. Results: No significant differences in cord OPN or ANGPTL8 levels were detected between the groups. However, the OPN levels in maternal serum and breast milk were greater in the GDM group than in the control group. We found an association between increasing maternal serum and breast milk OPN levels in quartile groups and the risk of GDM. Additionally, there was a moderate correlation between cord OPN and both maternal serum OPN (r = 0.45) and breast milk OPN (r = 0.43). Conclusions: The differences in OPN levels between the GDM and control groups suggest that OPN may reflect metabolic changes associated with GDM, possibly as a consequence of the condition itself or its treatment. Further research is necessary to validate these findings and uncover the underlying mechanisms involved. 1. Introduction Gestational diabetes mellitus (GDM), which is characterized by varying degrees of carbohydrate intolerance during pregnancy, poses significant risks to maternal and fetal health [1]. It is linked to serious perinatal outcomes such as macrosomia, birth trauma, hypoglycemia, and increased rates of cesarean section (C/S), along with long-term adverse effects such as type 2 diabetes mellitus (T2DM), obesity, and metabolic issues for both mothers and infants [2,3,4]. In 2021, approximately 21.1 million live births, accounting for 16.7% of pregnancies among women aged 20–49 globally, were affected by elevated blood glucose levels during pregnancy [5]. The identified risk factors include advanced maternal age, a high prepregnancy body mass index (BMI), and a family history of diabetes [6,7]. Mechanistically, GDM arises from impaired pancreatic cell function, particularly in the second and third trimesters, often culminating in insulin resistance mediated by proinflammatory cytokines [8]. Research endeavors to elucidate bioactive components contributing to GDM predictability, pathogenesis, and prognosis. Osteopontin (OPN), recognized as a proinflammatory cytokine, and betatrophin (ANGPTL8), a newly identified hormone, have emerged as potential candidates [9,10]. OPN, a acidic phosphoprotein, is synthesized in various tissues and is secreted into body fluids such as blood, urine, and breast milk. It plays a multifaceted role in inflammation, biomineralization, cell viability, and wound healing, with associations noted in cardiovascular diseases, various cancers, diabetes and obesity [11,12]. OPN exists in three isoforms (OPNa, OPNb and OPNc). In 2015, it was shown that there was a significant relationship between serum OPNc and diabetes and/or obesity in patients who had undergone pancreatic surgery [13]. OPN was observed to be expressed in pancreatic islets in nonobese diabetic mice and streptozotocin-induced diabetic (SID) rats [14,15]. Serum OPN levels have been shown to increase in patients with type 1 diabetes mellitus (T1DM), and higher OPN concentrations are associated with a dysmetabolic profile [16]. A study in pediatric patients revealed that high OPN levels are independently associated with T1DM, suggesting a potential role in predicting microvascular diabetic complications [17]. Animal models exposed to high-fat diets have shown increased expressions of OPN in adipose tissue macrophages, which is correlated with elevated plasma OPN levels and subsequent inflammation leading to obesity and insulin resistance [18]. Similarly, a study conducted in overweight/obese individuals demonstrated increased plasma OPN levels and mRNA expression in omental adipose tissue, with further elevation observed in individuals with obesity-associated diabetes [19]. Nevertheless, the relationship between OPN and the development and progression of GDM is not fully understood. Although experimental evidence suggests its involvement in GDM-associated inflammation, with potential therapeutic implications demonstrated in rodent models [20], human studies have reported inconsistent findings for GDM and OPN. In one of the studies, no significant association was found between OPN levels and insulin resistance in GDM patients, and OPN levels were linked to inflammatory markers and liver enzymes [21]. Similarly, two other investigations have not shown a significant relationship between OPN and GDM [22,23]. OPN is expressed in various tissues and body fluids, including blood, urine, and breast milk [16,24]. OPN is regarded as important in the growth of infants [25]. ANGPTL8, which is primarily expressed in the liver and secreted under conditions of insulin resistance, has garnered increasing attention for its involvement in glucose and lipid metabolism [26,27]. The overexpression of ANGPTL8 in SID mice resulted in an increase in β-cell numbers and insulin production and a decrease in glucose levels [10]. However, studies in pregnant women have yielded conflicting results regarding the association between ANGPTL8 levels and GDM, with some suggesting a positive association [28,29,30,31] and one reporting no significant relationship [32]. Additionally, research on the relationships between ANGPTL8 levels and diabetes and its complications remains scarce [31,33,34,35]. Furthermore, it has been shown that a high concentration of ANGPTL8 during the diagnosis of GDM is associated with a greater risk of T2DM in the postpartum period [36]. Moreover, studies indicate that ANGPTL8 levels are elevated in both maternal and cord blood of GDM patients, suggesting a potential role in reflecting intrauterine growth and fetal development [31,33,37]. On the other hand, ANGPTL8 is also secreted by the fetus itself [38]. Taken together, these findings suggest that circulating ANGPTL8 levels could serve as potential biomarkers for GDM, with implications for its diagnosis and prognosis. We hypothesized that OPN and ANGPTL8 levels will change in GDM-diagnosed mothers compared to those with a normal pregnancy course. Given the inconsistent findings in the literature, our study also aimed to compare OPN levels in three biomatrices [serum, cord blood, and postpartum breast milk (Day 10–15)] with ANGPTL8 levels in cord blood between mothers diagnosed with GDM and pregnant mothers with a normal course. Additionally, we plan to evaluate the relationships between these biomarkers and factors such as maternal anthropometric measurements, gestational weight gain, maternal body fat percentage, and infant birth weight. We anticipate that the results of this study will provide new insights into the etiology and monitoring of GDM. 2. Materials and Methods 2.1. Study Period The population of this case-control study included pregnant women who delivered at the Perinatology and Neonatology Clinic of Ankara Bilkent City Hospital, Health Sciences University, between 1 August 2021 and 1 August 2022. 2.2. Sample Size The sample size was calculated so that to detect a situation with an effect size of 0.5 (medium) with a two-way hypothesis with 90% power, 0.05 error, and a 1/1 case/control ratio, a total of 172 mothers, 86 mothers in each group, was necessary (G*Power Version, 3.1.9.4, Gachenbach, Germany). 2.3. Study Groups GDM Group: Pregnant women who presented to the perinatology outpatient clinic between the 24th and 28th weeks of pregnancy and who received a first-time diagnosis of GDM according to diabetes guidelines by a perinatology specialist were eligible for inclusion in this study. Pregnant women undergoing either dietary or insulin treatment were included without discrimination. Infants born at 37 weeks of gestation or later were eligible for inclusion, irrespective of being small for gestational age (SGA), appropriate for gestational age (AGA), or large for gestational age (LGA). Pregnant women with a prior diagnosis of diabetes mellitus, those with twin pregnancies, and those who did not provide informed consent were excluded from the GDM group. Control Group: Each pregnant woman who was diagnosed with GDM and included in the case group was matched with a control group consisting of a woman who delivered at the clinic on the same day, had no previous diagnosis of GDM or diabetes mellitus (DM), and had a singleton birth at 37 weeks of gestation or later. A total of 215 mothers were included in this study because 25% of the mothers might not have visited the control examination. Complete maternal serum, cord serum, and breast milk samples were obtained from 81 GDM patients and 84 control participants. A total of 165 patients were analyzed (Figure 1). In two cases, analysis could not be performed because the cord sample was insufficient. 2.4. Study Protocol Visit 1—Before delivery: Upon enrollment, pregnant women were informed about this study and signed consent forms prior to delivery and upon hospital admission. Sociodemographic characteristics and pregnancy-related information were collected through face-to-face interviews. Laboratory parameters obtained during pregnancy (including OGTT results, fasting blood glucose levels, and routine kidney and liver function tests) were extracted from patient files and hospital databases. Maternal blood samples for OPN levels were collected in gel-free tubes, with 7.5 mL taken just before delivery, left at room temperature for one hour, and then centrifuged at 3000 rpm for 10 min to obtain serum, which was aliquoted into three separate Eppendorf tubes and stored at −20 °C. Visit 2—At delivery: At the time of delivery, 5 mL cord blood samples for OPN and ANGPTL8 levels were collected in gel-free tubes. The samples were left at room temperature for one hour and then centrifuged at 3000 rpm for 10 min to obtain serum, which was aliquoted into two separate Eppendorf tubes and stored at −20 °C. Visit 3—Postpartum days 1–2: Breastfeeding counseling was given to the mothers after delivery. Maternal skinfold thicknesses were measured with a HOLTAIN skinfold caliper (Holtain, Crosswell, UK). The mother’s weight, body water percentage, body fat percentage, muscle mass, visceral fat mass, bone mass, metabolic age, and basal metabolic rate (BMR) were measured using a TANITA® BC 730 scale (TANITA, Tokyo, Japan) between 24 and 48 h after birth. The newborn’s birth weight, head circumference, and feeding method were recorded. Visit 4—Postpartum days 10–15: The 4th visit occurred during the newborn outpatient clinic check-up on days 10–15 after delivery. The infant’s characteristics, body weight at the control examination, nutritional status, and any problems, indirect hyperbilirubinemia history, and possible GDM complications were evaluated. The mothers’ body weight and body fat percentage were measured with a TANITA® BC 730 scale (TANITA, Tokyo, Japan). To measure OPN levels, while the infant was suckling from one breast, milk was obtained from the other breast using the manual milking method. Seven milliliters of breast milk was taken homogeneously into polypropylene Falcon tubes and stored at +4 °C. The sample was delivered to the laboratory for analysis within 24 h while maintaining the cold chain. 2.5. Storage and Analysis of Samples Serum samples were stored at Ankara Bilkent City Hospital at −20 °C in tubes in a separate cabinet until they reached the laboratory. The samples were delivered to the relevant laboratory by maintaining the cold chain. Breast milk samples were stored in 7 mL polypropylene tubes at −80 °C. The specimens were thawed at an ambient temperature following the manufacturer’s guidelines and prepared for analysis. OPN and ANGPTL8 levels were analyzed at Diagen Biotechnological Systems Health Services and Automation Industry and Trade Joint Stock Company (Ankara, Turkey). OPN concentrations were determined using an Elabscience® 96T Human OPN Enzyme Linked Immunosorbent Assay (ELISA) Kit (Elabscience, TX, USA) (Lot number: CV264T425582). ANGPTL8 concentrations were measured with an Elabscience® 96T Human ANGPTL8 (Angiopoietin Like Protein 8) Enzyme Linked Immunosorbent Assay (ELISA) Kit (Elabscience, TX, USA) (Lot number: CV24BN6L7456). Measurements were made without diluting the maternal serum by diluting the cord serum 20 times for OPN, 5 times for ANGPTL8, and 216,000 times for the milk. OPN and ANGPTL8 concentrations were determined by spectrophotometric measurements. 2.6. Statistical Analysis The data were coded in the IBM-SPSS 22.0 (IBM-SPSS Inc., Chicago, IL, USA) database. The acquired data underwent analysis using descriptive statistical techniques such as arithmetic mean, standard deviation, median, and percentage distributions. The means were compared between groups, and the normality of the distribution of the data was evaluated with the Shapiro–Wilk test. The “IDF” (inverse distribution function) correction, a two-step approach, has been applied to transform continuous variables that do not follow a normal distribution into a normal distribution [39]. To compare the means of two independent groups, the appropriate statistical test was chosen based on the parametric conditions. Specifically, the independent group t-test was employed when parametric conditions were satisfied, whereas the Mann–Whitney U test was utilized when parametric conditions were not met. Additionally, the chi-square test was applied to compare the percentage distributions of categorical data across different groups. Correlations between OPN levels and maternal and infant factors were evaluated with the Spearman correlation in both groups. Maternal serum and breast milk OPN levels were divided into quartiles, with the lowest quartile being “1” and the highest quartile being “4” (Q1–Q4). The chi-square test was used to compare the percentage distributions of GDM among quartile groups. Differences in subgroups were tested with adjusted residuals. Multiple logistic regression analysis revealed an association between GDM and the OPN quartile (Q2 vs. Q1; Q3 vs. Q1; Q4 vs. Q1) after adjusting for maternal parameters with p < 0.1 in univariate analysis [after selecting one of the correlated variables: maternal age, prepregnancy BMI (kg/m2), weight gain during pregnancy (adequate vs. insufficient, excessive vs. insufficient), gestational duration (weeks), body fat percentage, bone mass (kg), and body liquid percentage]. We computed odds ratios (ORs) along with their corresponding 95% confidence intervals (CIs). p < 0.05 was considered to indicate statistical significance. 3. Results A total of 165 patients with three complete samples—84 controls and 81 GDM patients—were included in this study. The mean age was 29.0 ± 5.6 years in the control group and 31.4 ± 5.4 years in the GDM group, and the mean age was significantly greater in the GDM group (p = 0.006, Table 1). While 84.5% of the participants in the control group were housewives, 77.8% of the participants in the GDM group were housewives. There was no significant difference between the two groups in terms of smoking history, spouse’s smoking history or passive smoking (Table 1). During pregnancy, while the frequency of hypertension was greater in the GDM group, the frequencies of anemia and hypothyroidism were similar in both groups (p = 0.001, 0.209, and 0.183, respectively; Table 1). The GDM diagnosis was made based on the results of the OGTT performed between weeks 24 and 28 of pregnancy (Supplementary Table S1). OGTTs were not performed in 29.8% of the control group, but blood glucose was monitored. OGTTs were performed for 87.7% of mothers diagnosed with GDM, and the remainder were diagnosed with high blood glucose. The frequency of polyhydramnios was greater in the GDM group than in the control group (p = 0.002, Table 1). The frequency of a maternal history of GDM and T2DM in first-degree relatives was significantly greater in the GDM group (p = 0.007 and 0.001, respectively). Obesity history during childhood, prepregnancy, and postnatal and 10–15-day postbirth BMI measurements were significantly greater in the GDM group (p = 0.048, p < 0.0001, p < 0.0001, and p < 0.0001, respectively; Table 1). The mean gestational duration was significantly lower in the GDM group than in the control group (37.7 ± 1.3 vs. 38.6 ± 1.2 weeks, p < 0.0001; Table 2). There were no significant differences in the 1st or 5th minute APGAR score, birth weight, head circumference, or chest circumference between the groups (p > 0.05). Both groups of newborns had similar discharge weights on day 2 (Table 3). The postnatal fat percentage, visceral fat, and metabolic age of mothers were significantly greater in the GDM group (p < 0.0001, <0.0001, and <0.0001, respectively). The body liquid percentage was greater in the control group (p < 0.0001). Bone mass, muscle mass, and the BMR were similar between the two groups (p > 0.05, Table 3). In terms of skinfold thickness, measurements taken from the biceps, triceps, and subscapular regions were significantly higher in mothers in the GDM group (p = 0.048, 0.002, and 0.005, respectively; Table 3). Between the 10th and 15th postnatal days, the GDM group exhibited higher levels of body fat percentage, visceral fat, muscle mass, the BMR, and metabolic age compared to the control group (p < 0.05, Table 3). 3.1. OPN and ANGPTL8 The levels of maternal serum OPN and breast milk OPN were significantly higher in the GDM group than in the control group (p = 0.002 and 0.002, respectively; Table 2). There was no significant difference in cord OPN or ANGPTL8 levels between the groups (p > 0.05, Table 2). According to sex, no significant differences were found in the levels of either ANGPTL8 or OPN among the three biomatrices in either study group (Supplementary Table S2). At discharge, the percentage of patients with insufficient breast milk was 21.4% in the control group and 33.3% in the GDM group. During the follow-up examination, the percentage of patients with breastfeeding problems was 50.6% in the GDM group and 35.7% in the control group. When milk OPN levels were examined according to the status of breast milk insufficiency at discharge and during follow-up in both study groups, no difference was detected (Table 4). The milk OPN value was higher in the GDM group without breast milk insufficiency in both periods compared to counterparts in control group, while no significant difference was found between the two groups having breastfeeding problems. The milk OPN value was found to be higher in the control group with breastfeeding problems than the control group without problems during the follow-up examination. In the control group, cord OPN and breast milk OPN values were higher in infants whose control weight was below the birth weight on the 10th–15th day, while cord ANGPTL8 levels were higher in the GDM group (Table 4). In the control group, the rate of receiving a diagnosis of jaundice requiring phototherapy was 12.0%, while, in the GDM-diagnosed group, this rate was 33.8%. Among patients without jaundice in the control group, cord ANGPTL8 levels were higher than those in the GDM group (p = 0.029, Table 5). When patients with mild jaundice were examined, both maternal serum OPN values and milk OPN values were higher in the GDM-diagnosed group (p = 0.011 and 0.007, respectively). When comparing cases without jaundice or with mild jaundice in the control group with cases requiring phototherapy, it was found that milk OPN values were higher significantly in the phototherapy group (p = 0.021). This association was not present in the GDM group (p = 0.368, Table 5). 3.2. The Associations of Maternal Serum and Breast Milk OPN with GDM When all mothers were included in the analysis, mothers with serum OPN-Q4 had higher percentages of GDM than mothers in other quartile levels of OPN. The GDM percentiles of mothers with Q3 and Q4 were detected to be higher than those of the other mothers (Table 6). After adjusting for maternal factors, maternal serum OPN levels in the fourth quartile were associated with a 3.19-fold higher likelihood of GDM compared to those in the first quartile (Table 6, Supplementary Table S3). Similarly, for milk OPN levels, the likelihood of GDM was 3.83 times higher in the fourth quartile than in the first quartile. 3.3. Correlation Between OPN Levels and Maternal-Infant Characteristics In both groups, there was a strong positive correlation between maternal serum OPN and breast milk OPN, as well as between maternal serum OPN and cord serum OPN (Table 7). In the control group, head circumference was negatively correlated with maternal serum OPN, while maternal age, metabolic age, head circumference, and chest circumference were negatively correlated with cord serum OPN. Maternal weight gain status, gestational age, head circumference, and chest circumference were negatively correlated with breast milk OPN. In the GDM group, metabolic age was positively correlated with maternal serum OPN. Maternal BMR was positively correlated with cord OPN, while maternal weight gain status, birth weight, bone mass, and muscle mass were negatively correlated with cord serum OPN. Gestational age was not associated with OPN levels. 4. Discussion Our study demonstrated that maternal serum OPN and breast milk OPN levels were associated with GDM. There are studies investigating OPN levels in both Type 1 and Type 2 diabetes [12,14,16,17]. In addition, Wang et al. documented that circulating OPN levels were elevated in individuals with NAFLD as well as in those with T2DM, regardless of the presence of NAFLD [40]. However, there is a scarcity of research exploring its association specifically with GDM. One study reported that OPN levels were associated with fasting blood OPN levels independent of GDM status and were elevated in overweight/obese individuals [41]. Two cross-sectional studies have examined the relationship between OPN and GDM, and OPN levels in blood samples taken during a certain period of pregnancy have been reported [21,22]. However, we have not yet conducted a study showing how OPN levels fluctuate throughout pregnancy and during childbirth. A 2012 study conducted by Winhofer et al. examined the serum OPN levels in pregnant women between 24 and 28 weeks of gestation, finding lower OPN levels in the GDM group compared to the control group, suggesting no relationship between insulin sensitivity and OPN [21]. Similarly, another study reported no association between OPN levels and GDM in serum samples taken at the 30th week of pregnancy [22]. However, in our study, the serum OPN levels of mothers before delivery were significantly higher in the GDM group than in the control group. The reason for this difference may be our larger sample size and sampling at a different gestational age compared to previous studies. In our study, we found that the milk OPN value was significantly higher in the control group experiencing breastfeeding problems than in the group without problems. More studies are needed to elucidate these contributing factors. Maternal stress, dietary changes and metabolic alterations may cause this discrepancy. There are previous studies reporting various changes in breast milk composition due to stress [42]. Consistent with the literature, our study revealed a greater incidence of neonatal phototherapy due to hyperbilirubinemia in the GDM group [43,44]. This highlights the need for more frequent monitoring of these infants for the early detection of jaundice and its complications. Unconjugated bilirubin levels are determined by the balance between bilirubin production and hepatic clearance. Hyperbilirubinemia can result from increased bilirubin production, decreased clearance or both, such as in cases of hemolysis [45]. Although GDM is known to be a risk factor for hyperbilirubinemia, further studies are needed to fully understand its mechanism. Additionally, we found significantly higher milk OPN values in patients who required phototherapy in the control group than in the group without jaundice or with mild jaundice (p = 0.021). To our knowledge, there are no studies investigating the relationship between jaundice and breast milk OPN levels. OPN derived from breast milk is resistant to digestion and can directly enter the circulation when ingested orally [46]. Therefore, it is believed that milk-derived OPN may play fundamental roles during the neonatal period. Breast milk OPN is suggested to play a role in numerous aspects of infant development, including intestinal proliferation and maturation, neurodevelopment, brain myelination, and immune system maturation [47]. One of the popular topics in recent years is that the content of breast milk may vary depending on the infant’s characteristics [48,49]. There are limited studies in the literature examining the relationship between jaundice and OPN, mainly limited to biliary atresia, one of the causes of pathological jaundice [50,51,52]. In this context, more studies are needed to elucidate the role of milk OPN in the mechanism of jaundice. From the perspective of OPN, a limitation of our study was that we collected maternal serum only during delivery, and the mothers who were diagnosed with GDM had undergone dietary changes and insulin therapy. OPN levels in maternal serum could not be measured at the time of GDM diagnosis. However, even in this scenario, we found that OPN levels in maternal serum significantly correlated with the risk of GDM. In our study, we also measured ANGPTL8 levels in cord blood. One study reported the involvement of ANGPTL8 in glucose and lipid metabolism [53]. A recent meta-analysis revealed an association between ANGPTL8 levels in maternal serum and GDM [54]. However, the results from studies conducted on cord blood are inconsistent [31,33,34,35]. ANGPTL8 levels are known to be associated with BMI and are increased in macrosomic infants [37]. We designed our study with a larger number of patients than did previous studies. Our results indicated no relationship between cord ANGPTL8 levels and medically well-controlled cases of GDM. There was no significant difference between the medically well-controlled GDM group and the typically healthy pregnant group in terms of birth weight. This suggests that mothers diagnosed with GDM had well-regulated glucose levels and complied with treatment, which might explain the lack of difference in ANGPTL8 levels between the two groups. A limitation of our study was the inability to measure ANGPTL8 levels in maternal serum. Therefore, we could not thoroughly examine the relationship between ANGPTL8 levels and GDM. To the best of our understanding, this study represents the inaugural exploration into the correlations among maternal serum, cord serum, and breast milk osteopontin (OPN) levels, as well as the concurrent interactions in cord serum ANGPTL8 levels, GDM history, and body composition. There is no published report on maternal serum OPN levels during childbirth. Contrary to previous studies [21,22,23], our data revealed an association with GDM, providing a new perspective on the levels of OPN in maternal serum and breast milk. Considering the characteristics of GDM, excessive weight gain during pregnancy and the higher birth weight of the newborn compared to the control group are commonly observed in GDM patients [55]. However, in our study, no significant difference was found between these two conditions among the groups. This might be due to the appropriate control of GDM cases. Previous studies have shown a strong correlation between the incidence of hypertension and polyhydramnios during pregnancy and GDM [56,57,58]. Our findings in this context are consistent with the literature. The greater incidence of childhood obesity, increased skinfold thickness, BMI, body fat percentage, and visceral fat in the GDM group than in the control group supports the relationship between weight gain and GDM observed in various studies [59,60,61]. GDM is a common multifactorial metabolic condition with long-term negative effects when complications develop. Despite numerous studies, treatment is limited to diet and medication therapy given after the onset of the disease [62,63]. Therefore, to reduce the risk of GDM, excessive weight gain should be prevented in pregnant women. However, in the GDM-diagnosed group, the higher rates of pathological weight loss at newborn discharge and the higher rates of formula feeding in the control group suggest the need for more careful breastfeeding support for the GDM group. Our study indicated that better counseling services should be provided to this group. Strengths and limitation of this Study: This study provides novel insights into the associations between maternal serum and breast milk OPN levels and GDM. Additionally, our larger sample size and inclusion of both maternal and cord blood samples strengthen the validity and generalizability of the findings. This study also sheds light on the potential role of breast milk-derived OPN in neonatal health, particularly its possible influence on neonatal jaundice and other developmental processes. Despite its strengths, this study has several limitations. First, the measurement of maternal serum OPN was only taken during delivery, and the potential effects of dietary changes and insulin therapy on OPN levels during the course of GDM management were not fully accounted for. The absence of OPN measurements at the time of GDM diagnosis limits our understanding of how early OPN changes might predict GDM outcomes. Additionally, while our study examined ANGPTL8 levels in cord blood, we could not assess ANGPTL8 in maternal serum, which restricts a comprehensive investigation into its role in GDM. The lack of longitudinal monitoring of OPN and ANGPTL8 levels throughout pregnancy also limits the ability to establish clear causal relationships. Finally, despite a large sample size, this study’s observational design does not allow for definitive conclusions regarding the underlying mechanisms of GDM and its impact on neonatal outcomes, necessitating further research to confirm these findings. 5. Conclusions Our findings indicated that maternal serum OPN levels at delivery were higher in the GDM group compared to the non-GDM group. This difference may reflect metabolic or inflammatory changes associated with GDM or its management during pregnancy. Factors such as dietary interventions, insulin therapy, or other aspects of GDM treatment could have influenced OPN levels. However, as OPN levels were not measured at the time of GDM diagnosis, it is not possible to determine whether the observed differences were due to GDM itself or its treatment. Future studies with prospective designs are needed to determine the temporal relationship between OPN levels and GDM, as well as to explore its potential as a biomarker for monitoring metabolic changes in pregnancy.